|Day Low/High||1.35 / 1.50|
|52 Wk Low/High||1.04 / 2.63|
Patients in All Cohorts Show Convincing Evidence of IL-12 Gene Transfer and Immune System Activity
When there is no real worry, stocks can keep on running, but the rampage in the Nasdaq 100 is not unlike frothy action of the past.
Strategic Move to Attract a Broader Range of Investors, to Ensure a Strong Balance Sheet, and to Enable the Expansion of the Company's Product Pipeline
Company to Hold Conference Call on Friday, May 12, 2017 at 11:00 a.m. ET
Patients in First Four Cohorts Show Clinically Meaningful Responses in the Evaluation of GEN-1, A Novel IL-12 DNA-based Immunotherapy, in Combination with the Standard of Care
Study's Lead Investigator to Report Updated Translational Research Data
Company to Hold Conference Call on Thursday, March 16, 2017 at 11:00 a.m. ET
Here's a technical look at how to trade several under-$10 stocks triggering breakout trades.
Strengthens Global Patent Portfolio Around Novel Heat-Sensitive Liposome Engineered to Address a Broad Range of Difficult-to-Treat Cancers
Study to Complete Final Patient Cohort as Planned